Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators

Edjah K. Nduom; Melanie Hayden Gephart; Milan G. Chheda; Mario L. Suva; Nduka Amankulor; James D. Battiste; Jian L. Campian; Ralph G. Dacey; Sunit Das; Peter E. Fecci; Constantinos G. Hadjipanayis; Kimberly B. Hoang; Ali Jalali; Daniel Orringer; Akash J. Patel; DImitris Placantonakis; Analiz Rodriguez; Isaac Yang; Jennifer S. Yu; Greg J. Zipfel; Gavin P. Dunn; Eric C. Leuthardt; Albert H. Kim

doi:10.1093/neuros/nyab063

Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators

Edjah K. Nduom, Melanie Hayden Gephart, Milan G. Chheda, Mario L. Suva, Nduka Amankulor, James D. Battiste, Jian L. Campian, Ralph G. Dacey, Sunit Das, Peter E. Fecci, Constantinos G. Hadjipanayis, Kimberly B. Hoang, Ali Jalali, Daniel Orringer, Akash J. Patel, DImitris Placantonakis, Analiz Rodriguez, Isaac Yang, Jennifer S. Yu, Greg J. ZipfelGavin P. Dunn, Eric C. Leuthardt, Albert H. Kim

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Patients with glioblastoma (GBM) need bold new approaches to their treatment, yet progress has been hindered by a relative inability to dynamically track treatment response, mechanisms of resistance, evolution of targetable mutations, and changes in mutational burden.We arewriting on behalf of amultidisciplinary group of academic neuro-oncology professionals who met at the collaborative Christopher Davidson Forum at Washington University in St Louis in the fall of 2019. We propose a dramatic but necessary change to the routine management of patients with GBM to advance the field: to routinely biopsy recurrent GBM at the time of presumed recurrence. Data derived from these samples will identify true recurrence vs treatment effect, avoid treatments with little chance of success, enable clinical trial access, and aid in the scientific advancement of our understanding of GBM.

Original language	English
Pages (from-to)	129-132
Number of pages	4
Journal	Neurosurgery
Volume	89
Issue number	1
DOIs	https://doi.org/10.1093/neuros/nyab063
State	Published - Jul 1 2021

Keywords

Clinical trials
Glioblastoma
Personalized medicine
Pseudoprogression
Recurrent glioblastoma
Stereotactic biopsy

Access to Document

10.1093/neuros/nyab063

Cite this

Nduom, E. K., Gephart, M. H., Chheda, M. G., Suva, M. L., Amankulor, N., Battiste, J. D., Campian, J. L., Dacey, R. G., Das, S., Fecci, P. E., Hadjipanayis, C. G., Hoang, K. B., Jalali, A., Orringer, D., Patel, A. J., Placantonakis, DI., Rodriguez, A., Yang, I., Yu, J. S., ... Kim, A. H. (2021). Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators. Neurosurgery, 89(1), 129-132. https://doi.org/10.1093/neuros/nyab063

@article{36f1ad089d9a4a22968e6bbcdcbdcda7,

title = "Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators",

abstract = "Patients with glioblastoma (GBM) need bold new approaches to their treatment, yet progress has been hindered by a relative inability to dynamically track treatment response, mechanisms of resistance, evolution of targetable mutations, and changes in mutational burden.We arewriting on behalf of amultidisciplinary group of academic neuro-oncology professionals who met at the collaborative Christopher Davidson Forum at Washington University in St Louis in the fall of 2019. We propose a dramatic but necessary change to the routine management of patients with GBM to advance the field: to routinely biopsy recurrent GBM at the time of presumed recurrence. Data derived from these samples will identify true recurrence vs treatment effect, avoid treatments with little chance of success, enable clinical trial access, and aid in the scientific advancement of our understanding of GBM.",

keywords = "Clinical trials, Glioblastoma, Personalized medicine, Pseudoprogression, Recurrent glioblastoma, Stereotactic biopsy",

author = "Nduom, {Edjah K.} and Gephart, {Melanie Hayden} and Chheda, {Milan G.} and Suva, {Mario L.} and Nduka Amankulor and Battiste, {James D.} and Campian, {Jian L.} and Dacey, {Ralph G.} and Sunit Das and Fecci, {Peter E.} and Hadjipanayis, {Constantinos G.} and Hoang, {Kimberly B.} and Ali Jalali and Daniel Orringer and Patel, {Akash J.} and DImitris Placantonakis and Analiz Rodriguez and Isaac Yang and Yu, {Jennifer S.} and Zipfel, {Greg J.} and Dunn, {Gavin P.} and Leuthardt, {Eric C.} and Kim, {Albert H.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s) 2021. Published by Oxford University Press, on behalf of the Society of Systematic Biologists.",

year = "2021",

month = jul,

day = "1",

doi = "10.1093/neuros/nyab063",

language = "English",

volume = "89",

pages = "129--132",

journal = "Neurosurgery",

issn = "0148-396X",

number = "1",

}

Nduom, EK, Gephart, MH, Chheda, MG, Suva, ML, Amankulor, N, Battiste, JD, Campian, JL, Dacey, RG, Das, S, Fecci, PE, Hadjipanayis, CG, Hoang, KB, Jalali, A, Orringer, D, Patel, AJ, Placantonakis, DI, Rodriguez, A, Yang, I, Yu, JS, Zipfel, GJ, Dunn, GP, Leuthardt, EC & Kim, AH 2021, 'Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators', Neurosurgery, vol. 89, no. 1, pp. 129-132. https://doi.org/10.1093/neuros/nyab063

TY - JOUR

T1 - Re-evaluating Biopsy for Recurrent Glioblastoma

T2 - A Position Statement by the Christopher Davidson Forum Investigators

AU - Nduom, Edjah K.

AU - Gephart, Melanie Hayden

AU - Chheda, Milan G.

AU - Suva, Mario L.

AU - Amankulor, Nduka

AU - Battiste, James D.

AU - Campian, Jian L.

AU - Dacey, Ralph G.

AU - Das, Sunit

AU - Fecci, Peter E.

AU - Hadjipanayis, Constantinos G.

AU - Hoang, Kimberly B.

AU - Jalali, Ali

AU - Orringer, Daniel

AU - Patel, Akash J.

AU - Placantonakis, DImitris

AU - Rodriguez, Analiz

AU - Yang, Isaac

AU - Yu, Jennifer S.

AU - Zipfel, Greg J.

AU - Dunn, Gavin P.

AU - Leuthardt, Eric C.

AU - Kim, Albert H.

PY - 2021/7/1

Y1 - 2021/7/1

N2 - Patients with glioblastoma (GBM) need bold new approaches to their treatment, yet progress has been hindered by a relative inability to dynamically track treatment response, mechanisms of resistance, evolution of targetable mutations, and changes in mutational burden.We arewriting on behalf of amultidisciplinary group of academic neuro-oncology professionals who met at the collaborative Christopher Davidson Forum at Washington University in St Louis in the fall of 2019. We propose a dramatic but necessary change to the routine management of patients with GBM to advance the field: to routinely biopsy recurrent GBM at the time of presumed recurrence. Data derived from these samples will identify true recurrence vs treatment effect, avoid treatments with little chance of success, enable clinical trial access, and aid in the scientific advancement of our understanding of GBM.

AB - Patients with glioblastoma (GBM) need bold new approaches to their treatment, yet progress has been hindered by a relative inability to dynamically track treatment response, mechanisms of resistance, evolution of targetable mutations, and changes in mutational burden.We arewriting on behalf of amultidisciplinary group of academic neuro-oncology professionals who met at the collaborative Christopher Davidson Forum at Washington University in St Louis in the fall of 2019. We propose a dramatic but necessary change to the routine management of patients with GBM to advance the field: to routinely biopsy recurrent GBM at the time of presumed recurrence. Data derived from these samples will identify true recurrence vs treatment effect, avoid treatments with little chance of success, enable clinical trial access, and aid in the scientific advancement of our understanding of GBM.

KW - Clinical trials

KW - Glioblastoma

KW - Personalized medicine

KW - Pseudoprogression

KW - Recurrent glioblastoma

KW - Stereotactic biopsy

UR - http://www.scopus.com/inward/record.url?scp=85108303811&partnerID=8YFLogxK

U2 - 10.1093/neuros/nyab063

DO - 10.1093/neuros/nyab063

M3 - Article

C2 - 33862619

AN - SCOPUS:85108303811

SN - 0148-396X

VL - 89

SP - 129

EP - 132

JO - Neurosurgery

JF - Neurosurgery

IS - 1

ER -

Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this